Results 91 to 100 of about 83,236 (262)

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

open access: yes
Arthritis &Rheumatology, EarlyView.
Kerem Abacar   +5 more
wiley   +1 more source

Immune Checkpoint Inhibitors Induce Intestinal Epithelial Injury and a Senescence‐Like Phenotype

open access: yesiNew Medicine, EarlyView.
ICI treatment promotes the infiltration of activated immune cells into the intestinal mucosa. This inflammatory microenvironment is associated with significant epithelial injury, characterized by the disruption of the epithelial barrier, the depletion of specialized secretory cell lineages, and the induction of a premature senescence phenotype ...
Juan Wang   +7 more
wiley   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu   +5 more
wiley   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

open access: yesiNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid   +4 more
wiley   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto   +7 more
wiley   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

open access: yesMed Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang   +9 more
wiley   +1 more source

High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome

open access: yesTherapeutic Advances in Medical Oncology
Background: CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents.
Nithya Krishnamurthy   +9 more
doaj   +1 more source

SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis ...
Maryam Jama   +2 more
wiley   +1 more source

Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
In this study, mean lung dose (MLD) and age were associated with an increased risk of treatment‐related pneumonitis in patients receiving concurrent chemoradiotherapy and immunotherapy, providing a reference for revising lung dose constraints. Abstract Objective Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively ...
Ying Lu   +9 more
wiley   +1 more source

Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis

open access: yesFrontiers in Endocrinology
ObjectiveImmune checkpoint inhibitors (ICIs) are revolutionary in oncology but may cause immune-related (IR) side effects, such as hypophysitis. Treatment with anti-PD-(L)1, anti-CTLA-4 or anti-CLTA-4/PD-1 may induce hypophysitis, but little is known ...
Stephanie van der Leij   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy